Arcutis Biotherapeutics announced that its topical PDE4 inhibitor ZORYVE® (roflumilast) cream received a strong recommendation with high certainty of clinical evidence in the American Academy of Dermatology’s (AAD) clinical practice guidelines for the management of pediatric atopic dermatitis. The guidelines, published online on April 7 2026, recommend ZORYVE 0.05 % for children aged 2‑5 years and 0.15 % for those 6 years and older, covering mild to moderate disease.
The endorsement follows FDA approvals that expanded ZORYVE’s pediatric indications: 0.05 % for ages 2‑5 years on October 6 2025 and 0.15 % for ages 6 years and older in July 2024. By adding a strong recommendation to the first‑ever pediatric AAD guidelines, the company reinforces its clinical position and signals that the steroid‑free, once‑daily therapy can be used anywhere on the body for any duration.
Arcutis’ commercial momentum is reflected in its 2025 financial results. Net product revenue for ZORYVE in Q4 2025 rose 84 % to $127.5 million, and full‑year 2025 net product revenue reached $372.1 million, a 123 % increase over 2024. The company raised its 2026 full‑year net product sales guidance to $480 million–$495 million, and Q4 2025 net income of $17.4 million replaced a $10.8 million loss in Q4 2024. The growth is driven by strong demand for the steroid‑free profile, pricing power, and operational leverage that has kept margins healthy.
CEO Frank Watanabe said, “In 2025, Arcutis continued its strong performance trend, with more than 90 % year‑over‑year growth in net product revenue, reflecting strong demand for ZORYVE, successful execution across multiple product launches that leveraged ZORYVE’s differentiated profile, and early penetration into the large topical steroid market.” Chief medical officer Patrick Burnett added, “The AAD’s strong recommendation for ZORYVE cream, building on its previous strong recommendation in adults, reflects the high certainty of evidence supporting its efficacy, low rates of treatment discontinuation, and favorable tolerability in pediatric patients.”
The guideline recommendation positions ZORYVE against a competitive landscape that includes topical corticosteroids, calcineurin inhibitors, crisaborole ointment, ruxolitinib cream, tapinarof cream, and systemic biologics such as dupilumab, tralokinumab, and lebrikizumab. ZORYVE’s steroid‑free, once‑daily regimen offers a distinct advantage for patients and clinicians seeking long‑term, body‑wide therapy without the side‑effects associated with chronic steroid use.
With an estimated 9.6 million U.S. children affected by atopic dermatitis and 1.8 million treated with topical therapy, the AAD endorsement is expected to accelerate prescription growth and expand market share. Arcutis’ strong cash position and investment in its pipeline provide the resources to sustain ZORYVE’s commercial momentum while advancing new indications and therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.